UNH
The subsidy era is over
CMS said it’s pulling the plug on the Medicare Part D Premium Stabilization Demonstration after the 2026 plan year. Translation: the government-backed cushion that helped keep prescription drug premiums from bouncing around like a shopping cart with one bad wheel is going away.
For seniors, that could mean higher monthly costs starting in 2027. For insurers like UnitedHealth Group, it means the market is moving back to a more traditional setup where plan sponsors have to stand on their own two feet when they bid for coverage.
Why investors should care
This is not a tiny policy tweak buried in the weeds. The WSJ reported the program is handing out about $3.6 billion in subsidies this year, and administration officials said more than half of that would have flowed to UnitedHealth had the program continued into 2027.
That matters because Part D pricing is a balancing act:
- Insurers want premiums low enough to stay competitive
- Medical and drug costs, especially GLP-1s and specialty meds, keep getting heavier
- CMS is signaling it thinks insurers can handle the mess without extra federal help
The premium squeeze
Officials are pitching the move as stabilization, not pain. They say:
- About 25% of enrollees could see premiums flat or lower in 2027
- Roughly 30% may see increases of less than $10 a month
- The rest could face hikes mostly in the $11 to $20 range
That’s not apocalypse stuff, but it is enough to keep the Medicare math interesting. And when a policy shift hits a business line as large as Medicare drug plans, investors tend to pay attention whether they own UNH or just like sleeping at night.
Big picture
The government is betting insurers can absorb more of the cost pressure on their own. UnitedHealth says it’s still committed to affordable prescriptions, but the direction of travel here is pretty clear: less subsidy, more pricing risk, and a bigger premium headache in 2027.